Recent meta-analyses have indicated an anti-obesity effect of GLP-1 receptor agonists, including liraglutide, exenatide, and semaglutide, particularly in obese individuals without diabetes. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.